By Matt Grossman 



  Eli Lilly & Co. said Friday that Reyvow, a drug it is developing for migraine attacks, achieved positive results in a Phase 3 trial. 


  The drug met all 18 patient-centric endpoints in the trial, Eli Lilly executive Dr. Mark Mintun said. People given the drug had between 3.8 times and 4.6 times greater odds of being pain-free two hours later compared with people who took a placebo, depending on the dose. 


  The drug also beat placebo results on measures of pain relief and easing of disability over a variety of time horizons, Eli Lilly said. 


  The study included 1,471 people who were randomly given either 100 milligrams or 200 milligrams of Reyvow or a placebo. Patients took the medication in response to at least moderate migraine attacks within four hours of the onset of pain. 


  The rate of serious adverse events from the drug was less than 1%. 


  Write to Matt Grossman at matt.grossman@wsj.com